These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 23334193)

  • 21. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
    Oyekunle A; Zander AR; Binder M; Ayuk F; Zabelina T; Christopeit M; Stübig T; Alchalby H; Schafhausen P; Lellek H; Wolschke C; Müller I; Bacher U; Kröger N
    Ann Hematol; 2013 Apr; 92(4):487-96. PubMed ID: 23250623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management.
    Martinelli G; Iacobucci I; Soverini S; Cilloni D; Saglio G; Pane F; Baccarani M
    Hematol Oncol; 2006 Dec; 24(4):196-204. PubMed ID: 16988930
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
    Kantarjian HM; Cortes J; Guilhot F; Hochhaus A; Baccarani M; Lokey L
    Cancer; 2007 Apr; 109(7):1365-75. PubMed ID: 17326047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Bcr-Abl inhibition as molecular therapy approach in chronic myeloid leukemia].
    Buchdunger E
    Med Klin (Munich); 2002 Jan; 97 Suppl 1():2-6. PubMed ID: 11831067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New tyrosine kinase inhibitors in chronic myeloid leukemia.
    Martinelli G; Soverini S; Rosti G; Cilloni D; Baccarani M
    Haematologica; 2005 Apr; 90(4):534-41. PubMed ID: 15820950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic myeloid leukemia in children: clinical findings, management, and unanswered questions.
    Hijiya N; Millot F; Suttorp M
    Pediatr Clin North Am; 2015 Feb; 62(1):107-19. PubMed ID: 25435115
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All is not lost in accelerated phase/blast crisis and after tyrosine kinase inhibitors fail in chronic myeloid leukaemia: a retrospective study of allogeneic stem cell transplant outcomes in Australia and New Zealand.
    Kruger P; Cooney J; Nivison-Smith I; Dodds A; Bardy P; Ma D; Szer J; Durrant S
    Bone Marrow Transplant; 2016 Oct; 51(10):1400-1403. PubMed ID: 27214080
    [No Abstract]   [Full Text] [Related]  

  • 31. Contribution of Chronic Myeloid Leukaemia (CML) as a Disease Model to Define and Study Clonal Heterogeneity.
    Berger MG; Bourgne C
    Adv Exp Med Biol; 2019; 1139():171-185. PubMed ID: 31134501
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in targeted therapy of human myelogenous leukaemia.
    Paz K; Zhu Z
    Expert Opin Ther Targets; 2005 Dec; 9(6):1147-63. PubMed ID: 16300467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cancer therapy: The leukaemia epigenome targeted.
    Losman JA
    Nature; 2017 Mar; 543(7647):634-635. PubMed ID: 28358070
    [No Abstract]   [Full Text] [Related]  

  • 34. The Contemporary Role of Hematopoietic Stem Cell Transplantation in the Management of Chronic Myeloid Leukemia: Is It the Same in All Settings?
    Elmakaty I; Saglio G; Al-Khabori M; Elsayed A; Elsayed B; Elmarasi M; Elsabagh AA; Alshurafa A; Ali E; Yassin M
    Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 3-Aroyl-1,4-diarylpyrroles Inhibit Chronic Myeloid Leukemia Cell Growth through an Interaction with Tubulin.
    La Regina G; Bai R; Coluccia A; Famiglini V; Passacantilli S; Naccarato V; Ortar G; Mazzoccoli C; Ruggieri V; Agriesti F; Piccoli C; Tataranni T; Nalli M; Brancale A; Vultaggio S; Mercurio C; Varasi M; Saponaro C; Sergio S; Maffia M; Coluccia AML; Hamel E; Silvestri R
    ACS Med Chem Lett; 2017 May; 8(5):521-526. PubMed ID: 28523104
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling.
    Frolov A; Evans IM; Li N; Sidlauskas K; Paliashvili K; Lockwood N; Barrett A; Brandner S; Zachary IC; Frankel P
    Sci Rep; 2016 Jun; 6():27378. PubMed ID: 27293031
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies.
    Xu MM; Pu Y; Zhang Y; Fu YX
    Trends Immunol; 2016 Feb; 37(2):141-153. PubMed ID: 26778079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myeloid derived suppressor cells in chronic myeloid leukemia.
    Giallongo C; Parrinello N; Brundo MV; Raccuia SA; Di Rosa M; La Cava P; Tibullo D
    Front Oncol; 2015; 5():107. PubMed ID: 26029664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The next questions in chronic myeloid leukaemia and their answers.
    Marin D; Rotolo A; Milojkovic D; Goldman J
    Curr Opin Hematol; 2013 Mar; 20(2):163-8. PubMed ID: 23334193
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current opinions and controversies in chronic myeloid leukaemia.
    Kishore B; Marin D
    Curr Opin Oncol; 2011 Nov; 23(6):659-64. PubMed ID: 21918441
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.